PTPA and acute myeloid leukemia: In this regard, the tumor-suppressor PP2A has emerged as a promising therapeutic target in AML, since it is a negative regulator of several survival and proliferation pathways that are frequently activated in AML as a result of aberrant activation of oncogenic kinases.